GREGORY FLEMING JAMES CYSTIC FIBROSIS RESEARCH CENTER

Director: Steven M. Rowe, MD, MSPH
https://www.uab.edu/medicine/cysticfibrosis/

The Gregory Fleming James Cystic Fibrosis (CF) Research Center was established in 1981 at UAB as a multidisciplinary Center to study CF basic research and therapy. Also in 1981, the CF Foundation began an initiative for funding CF research known as the Research Development Program (RDP). UAB was chosen as the first to receive RDP support from the foundation, which now sponsors 10 such Centers in the United States. The Center has since maintained continuous CF Foundation and NIH funding, which has been supplemented by University Wide Interdisciplinary Research Center (UWIRC) and other important funding from the University and the State of Alabama.

Together, this support has fostered the Center’s sustained legacy of advancing scientific success in CF, which was recognized through the recent renewal of its NIDDK seed funding (1 of only 3 Centers selected nationwide) and RDP funding. Multidisciplinary collaborations across UAB and beyond—cultivated in part by the unique and cutting-edge facilities, techniques, and resources offered through the Center’s 6 Cores—have been fundamental in driving these achievements and are a defining feature of our Center.

The CF Care Center located at the Children’s Hospital of Alabama and UAB Hospital provides state-of-the-art care for approximately 500 CF patients, generating additional partnerships across departments and specialties.

### Functional Assay Core
James F. Collawn, PhD

- Monitoring of ion transport in CF and control cells and tissue
  - Ussing chamber analyses
  - Transepithelial chloride conductance (TECC) using robots that calculate changes in conductance or equivalent current in high-throughput formats

- Measurements of mucociliary transport and fluid flux
  - µOCT imaging of freshly harvested trachea with or without further experimental exposures ex vivo
  - Quantitation of organoid swelling derived from airway cells, intestinal organoids, and iPSC-derived spheroids

- Patch clamp and single-channel analyses to study changes in CFTR channel gating and regulation
  - Patch clamp unitary conductance tracings to monitor open channel probability and test potentiators (or correctors) on a wide spectrum of CF mutations. Mutagenesis evaluations can be coupled to uncover mechanisms
  - Macropatch of cells or excised tissues or fluorescent dye-halide efflux methods to evaluate CFTR activity in cells grown on coverslips (SPQ assays) or isolated from excised tissues

### CF Clinical & Translational Assay Core
Steven Rowe, MD, MSPH and Amit Gaggar, MD, PhD

- Designs and conducts in vivo measurements of CFTR activity in humans
  - Nasal potential difference (NPD)
  - PD measurements of the lower airway and sinus tract (by the endoscopic approach)
  - Sweat chloride analysis / sweat rate
  - Rectal intestinal current measurements

- Conducts cardinal measures of airway epithelial cell function in vivo
  - µOCT imaging for in vivo use by endoscopic probes
  - Whole lung MOC by Tc99 clearance approach

- Supports the execution of CF clinical studies
  - Clinical trial design and regulatory support
  - Collection and storage of biospecimens
  - Supports key clinical outcome measures in infants, children, and adults with CF (nutritional outcomes, spirometry, lung clearance index (LCI), and infant PFTs)

### Cell Model and Evaluation Core
George Solomon, MD and Bradford Woodworth, MD

- Procures, grows, and distributes well-differentiated primary human airway epithelial cells from CF and non-CF donors
- Conducts functionalatomic imaging of airway epithelia by µOCT in vitro and ex vivo
  - Well-differentiated primary epithelial cells (of human or non-human origin)
  - Intact full-thickness trachea or mainstem bronchus of human origin

- Performs measures of CFTR activity and expression in primary cells
  - Ussing chamber analyses, high-throughput evaluation by equivalent and transepithelial conductance (GI) and equivalent current (IE)
  - Western blot, digital mRNA analysis utilizing primary cells on permeable supports

### CF Animal and Preclinical Models Core
David M. Bedwell, PhD

- Breeds, genotypes, and distributes CF knockout mice and CF mice harboring clinically relevant mutations
  - Cfrtm1Cam, Cfrtm1Cam-Erasmus, Cfrtm1G551D, Cfrtm1G551D and others

- Generates and procures relevant CF animal models
  - Includes analysis and procurement of pig, ferret (and very recently, CF rabbit tissues), and maintains a colony of ferrets to evaluate acquired CFTR dysfunction and therapeutic approaches

- Conducts endpoint measures to assess CFTR Function, epithelial physiology, preclinical endpoints, and biospecimen analysis in CF animal models
  - Nasal and lower airway potential difference
  - Short circuit current (Isc) measurements of excised trachea and intestine
  - Measurement of lung function (Flexivent)
  - In vivo and ex vivo µOCT imaging (can be supplemented with in vivo microscopy)
  - 6-Voxel resolution computed tomography
  - Abdominal ultrasound
  - Cough monitoring
  - Glundolary CFTR assay
  - Electro-procuration-mediated gene manipulation
  - Microarray chromoscopy for longitudinal lung sampling
  - Anesthesia, physiologic monitoring, intubation for exposure and assessment procedures

### Gene Expression Core
Lianlu Fu, PhD

- Cloning of new CFTR constructs and other CFTR regulatory proteins
  - Provided across widely used durable cell types (e.g., FRT, Calu-3) and airway-specific cell expression systems emerging in their importance (e.g., 16HBE14o-)
  - CFBE41o-
  - Viral and plasmid-based protocols

- Creation of cell lines for investigating CFTR biology and therapy
  - Large variety of plasmid-based CFTR vectors: CFTR-GFP fusions, individual CFTR domains, eukaryotic expression vectors, glycogen mutants, epithole tagged CFTR, and over 50 clinical CFTR mutations or small deletions

- Assistance with studies of precise detection of CFTR mRNA and protein expression
  - Assays include PCR, Western blotting, digital PCR, RNAscope, ribosomal profiling
  - Maintains shRNA and antisense oligonucleotide capabilities for knock-down and gene editing of CFTR and other cellular targets relevant to CF pathogenesis

- Provides a bridge to collaboration with single-cell RNA sequencing and analysis on campus, and consultation for studies of CFTR biogenesis (e.g., imunophenecipation, pulse-chase, cell surface bioluminiscence, and other biotechnical means

### CFTR Rat Models Core
Susan S. Birket, PharmD, PhD

- Breeds, genotypes, and distributes diverse CF rat models and their tissues
  - CFTR-/-, N5551D, and G542X rats, in addition to maintenance of WT Sprague Dawley

- Provides state-of-the-art endpoints in CF rat models with and without infection to elucidate disease mechanism, analyze pathways, or predict clinically relevant findings

- CFTR physiological outcome measures (NPD, secretion secretion)
- Assays of lung structure and function (micro-CT imaging, Flexivent, in vivo microscopy)
- Collection and banking of biospecimens (survival Schematic of the nasal potential difference apparatus

- Employment by the CF mouse models core.

- Widely used on type (larger) mice bred in the CF mouse models core.

### Other diseases related to CFTR defects studied in UAB CF cores

- COPD (chronic obstructive pulmonary disease)
- ABPA (allergic bronchopulmonary aspergillosis)
- IB (idiopathic bronchiectasis)
- CRS (chronic rhinosinusitis)
- Primary Ciliary Dyskinesia
- Asthma
- Cholestera
- Other enterotoxicogenic diarrheal diseases
- CBW9 (congenital absence of the vas defensins, male infertility)
- PKD (polycystic kidney disease)
- IFP (idiopathic fibrosis)